End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17

Eurosurveillance

Volumn 22, Issue 44, 2017, Pages

  Pebody, Richard ^a   Warburton, Fiona ^a   Ellis, Joanna ^a   Andrews, Nick ^a   Potts, Alison ^b   Cottrell, Simon ^c   Reynolds, Arlene ^b   Gunson, Rory ^d   Thompson, Catherine ^a   Galiano, Monica ^a   Robertson, Chris ^e   Gallagher, Naomh ^f   Sinnathamby, Mary ^a   Yonova, Ivelina ^g,h   Correa, Ana ^g   Moore, Catherine ^c   Sartaj, Muhammad ^f   de Lusignan, Simon ^g,h   McMenamin, Jim ^b   Zambon, Maria ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b HEALTH PROTECTION SCOTLAND   (United Kingdom)

^c PUBLIC HEALTH WALES   (United Kingdom)

^d West of Scotland Specialist Virology Laboratory Gartnavel   (United Kingdom)

^e UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^f PUBLIC HEALTH AGENCY   (United Kingdom)

^g UNIVERSITY OF SURREY   (United Kingdom)

^h ROYAL COLLEGE OF GENERAL PRACTITIONERS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; COOKING; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; PUBLICATION; WRITING; ADOLESCENT; AGED; CASE CONTROL STUDY; CHILD; EPIDEMIC; GENETICS; HEALTH SURVEY; IMMUNOLOGY; INFANT; INFLUENZA; INFLUENZA A VIRUS; INFLUENZA B VIRUS; ISOLATION AND PURIFICATION; MIDDLE AGED; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; PRIMARY HEALTH CARE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SENTINEL SURVEILLANCE; STATISTICS AND NUMERICAL DATA; UNITED KINGDOM; VACCINATION; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

INFLUENZA VACCINE; LIVE VACCINE; VACCINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POPULATION SURVEILLANCE; PRIMARY HEALTH CARE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SENTINEL SURVEILLANCE; UNITED KINGDOM; VACCINATION; VACCINE POTENCY; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 85035025202     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2017.22.44.17-00306     Document Type: Article

References (29)

1. Public Health England (PHE). Department of Health. Flu Plan. Winter 2016/17. London: PHE; May 2016. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/525967/Annual_flu_plan_2016_to_2017.pdf
2. Hakin B, Cosford P, Harvey F. The flu immunisation programme 2013/14– extension to children. London: Department of Health; 26 Jul 2013. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/225360/Children_s_flu_letter_2013.pdf
3. Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S, et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Euro Surveill. 2016;21(38):30348. https://doi.org/10.2807/1560-7917.ES.2016.21.38.30348 PMID: 27684603
4. Grohskopf LA, Sokolow LZ, Broder KR, Olsen SJ, Karron RA, Jernigan DB, et al. Prevention and Control of Seasonal Influenza with Vaccines. MMWR Recomm Rep. 2016;65(5):1-54. https://doi.org/10.15585/mmwr.rr6505a1 PMID: 27560619
5. Penttinen PM, Friede MH. Decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines: an observational bias or a technical challenge? Euro Surveill. 2016;21(38):30350. https://doi.org/10.2807/1560-7917.ES.2016.21.38.30350 PMID: 27684999
6. Public Health England (PHE).Weekly National Flu Report. London: PHE; 19 Jan 2017. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/584583/Weekly_national_influenza_report_week_03_2017.pdf
7. Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, et al. Serial vaccination and the antigenic distance hypothesis: effects on influenza vaccine effectiveness during A(H3N2) epidemics in Canada, 2010-11 to 2014-15. J Infect Dis. 2017;215(7):1059-99. https://doi.org/10.1093/infdis/jix074 PMID: 28180277
8. Fleming DM, Andrews NJ, Ellis JS, Bermingham A, Sebastianpillai P, Elliot AJ, et al. Estimating influenza vaccine effectiveness using routinely collected laboratory data. J Epidemiol Community Health. 2010;64(12):1062-7. https://doi.org/10.1136/jech.2009.093450 PMID: 19910645
9. World Health Organization (WHO). WHO Consultation and Information Meeting on the Composition of Influenza Virus Vaccines for Use in the 2017-2018 Northern Hemisphere Influenza Season. Geneva: WHO; 20 Dec 2016. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/consultation201702/en/
10. Gunson R, Maclean A, Davies E, Bennett S, Miller R, Carman WF. Development of a multiplex real-time RT-PCR that allows universal detection of influenza A viruses and simultaneous typing of influenza A/H1N1/2009 virus. J Virol Methods. 2010;163(2):258-61. https://doi.org/10.1016/j.jviromet.2009.10.006 PMID: 19854220
11. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol. 2003;77(15):8418-25. https://doi.org/10.1128/JVI.77.15.8418-8425.2003 PMID: 12857911
12. Zambon M. Laboratory Diagnosis of Influenza. In: Nicholson K, Hay A, Webster RG, editors. Textbook of Influenza. Oxford: Blackwell Science; 1998. pp. 291-313.
13. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol. 2013;30(12):2725-9. https://doi.org/10.1093/molbev/mst197 PMID: 24132122
14. Kissling E, Rondy MI-MOVE/I-MOVE+ study team. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. Euro Surveill. 2017;22(7):30464. https://doi.org/10.2807/1560-7917.ES.2017.22.7.30464 PMID: 28230524
15. Flannery B, Chung JR, Thaker SN, Monto AS, Martin ET, Belongia EA, et al. Interim Estimates of 2016-17 Seasonal Influenza Vaccine Effectiveness -United States, February 2017. MMWR Morb Mortal Wkly Rep. 2017;66(6):167-71. https://doi.org/10.15585/mmwr.mm6606a3 PMID: 28207689
16. Skowronski DM, Chambers C, Sabaiduc S, Dickinson JA, Winter AL, De Serres G, et al. Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017. Euro Surveill. 2017;22(6):30460. https://doi.org/10.2807/1560-7917.ES.2017.22.6.30460 PMID: 28205503
17. Hergens MP, Baum U, Brytting M, Ikonen N, Haveri A, Wiman Å, et al. Mid-season real-time estimates of seasonal influenza vaccine effectiveness in persons 65 years and older in registerbased surveillance, Stockholm County, Sweden, and Finland, January 2017. Euro Surveill. 2017;22(8):30469. https://doi.org/10.2807/1560-7917.ES.2017.22.8.30469 PMID: 28251891
18. Skowronski DM, Chambers C, Sabaiduc S, Dickinson JA, Winter AL, De Serres G, et al. Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017. Euro Surveill. 2017;22(6):30460. https://doi.org/10.2807/1560-7917.ES.2017.22.6.30460 PMID: 28205503
19. McLean HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M, Murthy K, et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015;211(10):1529-40. https://doi.org/10.1093/infdis/jiu647 PMID: 25406334
20. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942-51. https://doi.org/10.1016/S1473-3099(16)00129-8 PMID: 27061888
21. Shay DK, Chillarige Y, Kelman J, Forshee RA, Foppa IM, Wernecke M, et al. Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries in Preventing Postinfluenza Deaths During 2012-2013 and 2013-2014. J Infect Dis. 2017;215(4):510-7. https://doi.org/10.1093/infdis/jiw641 PMID: 28329311
22. Ambrose CS, Bright H, Mallory R. Letter to the editor: Potential causes of the decreased effectiveness of the influenza A(H1N1) pdm09 strain in live attenuated influenza vaccines. Euro Surveill. 2016;21(45):30394. http://dx.doi.org/https://doi.org/10.2807/1560-7917.ES.2016.21.45.30394 PMID:27918259
23. Pebody RG, Green HK, Andrews N, Boddington NL, Zhao H, Yonova I, et al. Uptake and impact of vaccinating school age children against influenza during a season with circulation of drifted influenza A and B strains, England, 2014/15. Euro Surveill. 2015;20(39):30029. https://doi.org/10.2807/1560-7917.ES.2015.20.39.30029 PMID: 26537222
24. Caspard H, Mallory RM, Yu J, Ambrose CS. Live-Attenuated Influenza Vaccine Effectiveness in Children From 2009 to 2015-2016: A Systematic Review and Meta-Analysis. Open Forum Infect Dis. 2017;4(3):ofx111. https://doi.org/10.1093/ofid/ofx111 PMID: 28852675
25. Pebody R, McMenamin J, Nohynek H. Live attenuated influenza vaccine (LAIV): recent effectiveness results from the USA and implications for LAIV programmes elsewhere. Arch Dis Child. 2017 Aug 30. pii: archdischild-2016-312165. doi: https://doi.org/10.1136/archdischild-2016-312165
26. Nohynek H, Baum U, Syrjänen R, Ikonen N, Sundman J, Jokinen J. Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds -a nationwide cohort study Finland, influenza season 2015/16. Euro Surveill. 2016;21(38):30346. https://doi.org/10.2807/1560-7917.ES.2016.21.38.30346 PMID: 27684447
27. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2017-2018 northern hemisphere influenza season. Geneva: WHO; 2 Mar 2017. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/2017_18_north/en/
28. Hodgson D, Baguelin M, Leeuwen E, Panovska-Griffiths J, Ramsay M, Pebody R, Atkins KE. Effect of mass paediatric infl uenza vaccination on existing infl uenza vaccination programmes in England and Wales: a modelling and costeffectiveness analysis. Lancet Public Health Published Online January 10, 2017. http://dx.doi.org/https://doi.org/10.1016/S2468-2667(16)30044-5.
29. Loeb M, Russell ML, Manning V, Fonseca K, Earn DJ, Horsman G, et al. Live Attenuated Versus Inactivated Influenza Vaccine in Hutterite Children: A Cluster Randomized Blinded Trial. Ann Intern Med. 2016;165(9):617-24. https://doi.org/10.7326/M16-0513 PMID: 27538259